[The role of pathology in the predictive oncology of solid tumours].
Recently, a new generation of pharmacons that are aimed to hit specific molecular targets has entered the oncology. Currently, testing of tumour tissue for the presence of particular molecules is needed. Those molecular entities predict probability of response to the targeted therapy. On a model of steroid hormone receptors and HER2 status testing a process of the predictive diagnostics is demonstrated. A contemporary concept of predictive oncology in the Czech Republic consisting of six "Predictive Oncology Laboratories" is described. Surgical pathology is shown as a key partner in the predictive oncology system.
Oddelení onkologické a experimentální patologie. Masarykův onkologický ústav, Brno. fabian@mou.cz
Pavel
P
Fabian
D001943:Breast Neoplasms / Q000378:metabolism / Q000628:therapy; D066246:ErbB Receptors / Q000378:metabolism; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D057285:Precision Medicine; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism
D066246:ErbB Receptors; D018719:Erb-b2 Receptor Tyrosine Kinases